Amgen appointed Naveen Gullapalli, former Novartis executive, as Managing Director of Amgen India. Gullapalli will lead Amgen ...

Naveen Gullapalli has been appointed as Managing Director of Amgen's India Technology and Innovation Hub in Hyderabad, ...

Gullapalli will oversee the Amgen India Technology and Innovation hub, leveraging his extensive expertise in global ...

Amgen appoints Naveen Gullapalli as managing director to accelerate tech & innovation from India: Our Bureau, Bengaluru ...

THOUSAND OAKS, Calif., Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday, Dec. 5, 2024. Peter Griffith ...

Amgen (NASDAQ: AMGN) offers an intriguing test case for this dynamic heading into 2025. The biotech-giant's shares have slumped 3.37% in 2024, while the S&P 500 has surged 26.8% as of this writing ...

An Amgen manufacturing facility in Thousand Oaks, California. In 2025, the company plans to open a manufacturing site in Holly Springs, North Carolina. DANIEL HENNESSY Photo courtesy of Amgen The ...

Amgen Inc (Symbol: AMGN) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

(RTTNews) - Amgen (AMGN) announced new data from a Phase 3 study demonstrating that adding BLINCYTO (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly ...